US benefits provider launches genetic testing division

The US family-building benefits provider Kindbody has launched its in-house genetic testing division.

Kindlabs will offer a genetic testing platform, from wet lab chemistry to software and bioinformatics, hoped to provide medical-grade genetic tests at price points to help to democratise access to genomic information.

The addition of the new division will incorporate genomics into the company’s end-to-end model, with the aim to deliver a “continuum of care” to patients.

Kindlabs will operate its reference laboratory in Secaucus, New Jersey, under the leadership of Dr Amber Cooper, Kindbody’s chief medical officer of genomics and laboratory sciences, and Manuel Viotti, vice president of preimplantation genetic testing and clinical laboratory director.

“Under the visionary leadership of Dr Viotti, our dedicated scientific team has made significant strides in advancing genomic sequencing analysis for the benefit of patients,” said Cooper.

“Dr Viotti’s instrumental role in spearheading the development of Kindlabs has positioned Kindbody as leaders in the industry. Together, our team is revolutionising genomic analysis, delivering valuable improvements that positively impact patients’ lives.”

Dr Angeline Beltsos, CEO, clinical, at Kindbody, said: “At the heart of Kindbody’s mission is to help build healthy families for our patients.

“The addition of Kindlabs combines industry-leading technology and expertise, and stringent quality standards, to optimise our patients’ chances of achieving a successful pregnancy and bringing home a healthy baby.”

Kindbody says its clinically-managed programme covers the full-spectrum of reproductive health, including both female and male fertility, as well as a full continuum of reproductive care including physical, mental, and emotional support.

The company owns and operates 32 clinics throughout the US, including in California, Texas, Michigan, New York and Wisconsin.